https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45208 Wed 26 Oct 2022 15:56:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36854 Wed 24 Nov 2021 15:53:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47089 Wed 14 Dec 2022 09:30:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:9418 Wed 11 Apr 2018 17:00:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:12741 Wed 11 Apr 2018 16:32:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20993 Wed 11 Apr 2018 15:59:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22705 n=174) were randomly allocated to the face-to-face, group-based intervention (six, theory-based two-hour sessions delivered over 8weeks targeting healthy eating and physical activity [PA]) or wait-list control (after completion of 20-week data collection). Assessment of the primary outcome (pedometer-assessed mean daily step counts) and secondary outcomes (diet and alcohol intake [Food Frequency Questionnaire], self-reported PA, weight, body mass index, and waist circumference) were assessed at baseline, 8-and 20-weeks. Results: There was a significant difference between the change over time in the intervention group and the control group. At 20weeks, the intervention group had increased by 478 steps, and the control group had decreased by 1282 steps; this represented an adjusted mean difference of 1761 steps (184 to 3337; P=0.0028). Significant intervention effects for secondary outcomes, included a half serving increase in vegetable intake (difference 39g/day; 95% CI: 12 to 67; P=0.02), weight loss (kg) (difference -1.5kg; 95% CI, -2.6 to -0.3; P=0.014) and change in body mass index (kg/m2) (difference -0.55kg/m2; 95% CI, -0.97 to -0.13; P=0.012). No significant intervention effects were found for self-reported PA, total sitting time, waist circumference, fruit, energy, fibre, alcohol, meat, or fat consumption. Conclusions: The ENRICH intervention was effective for improving PA, weight, body mass index, and vegetable consumption even with the inclusion of multiple cancer types and carers. As an example of successful research translation, the Cancer Council NSW has subsequently adopted ENRICH as a state-wide program. Trial registration: Australian New Zealand Clinical Trials Register identifier: ANZCTRN1260901086257.]]> Wed 11 Apr 2018 15:23:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7313 Wed 11 Apr 2018 15:05:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15944 Wed 11 Apr 2018 14:57:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14865 Wed 11 Apr 2018 14:49:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28423 Wed 11 Apr 2018 14:49:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22771 Wed 11 Apr 2018 14:41:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15204 Wed 11 Apr 2018 13:36:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:24864 Wed 11 Apr 2018 12:41:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7726 Wed 11 Apr 2018 11:57:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13998 Wed 11 Apr 2018 11:35:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13573 Wed 11 Apr 2018 11:32:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14167 Wed 11 Apr 2018 10:41:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:40943 Wed 10 May 2023 10:32:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:29559 G and c.3113G > A, CHEK2 c.349A > G, c.538C > T, c.715G > A, c.1036C > T, c.1312G > T, and c.1343T > G and ATM c.7271T > G. We assessed associations with breast cancer risk (42 671 cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 542 cases and 23 491 controls) cancer risk, for each variant. Results: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10-5), PALB2 c.3113G > A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10-8) and ATM c.7271T > G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A > G OR 2.26 (95% CI 1.29 to 3.95), c.1036C > T OR 5.06 (95% CI 1.09 to 23.5) and c.538C > T OR 1.33 (95% CI 1.05 to 1.67) (p=0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T > G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G > T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants. Conclusions This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important.]]> Wed 09 Feb 2022 15:56:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43998 Wed 05 Oct 2022 15:10:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46707 1-3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4-5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter⁴; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation^5,6; analyses timings and patterns of tumour evolution⁷; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity^8,9; and evaluates a range of more-specialized features of cancer genomes^8,10-18.]]> Tue 29 Nov 2022 11:22:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36524 Tue 26 May 2020 14:30:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47647 P = 0.007) and for those under 65 (19.0%; 95% CI, 8.1–28.6%) than for older people (6.6%; 95% CI, 1.9–11.1%; P = 0.030). There were no independent relationships between body mass index or alcohol consumption and pancreatic cancer. Conclusions: Strategies that reduce the uptake of smoking and encourage current smokers to quit could substantially reduce the future incidence of pancreatic cancer in Australia, particularly among men.]]> Tue 24 Jan 2023 14:51:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20561 Tue 10 Oct 2023 08:38:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38190 Tue 10 Aug 2021 16:00:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36703 Thu 25 Jun 2020 11:30:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:30583 Thu 17 Mar 2022 14:38:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46914 Thu 08 Dec 2022 08:47:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51478 Thu 07 Sep 2023 10:53:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14002 Sat 24 Mar 2018 10:38:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1412 Sat 24 Mar 2018 08:28:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10469 Sat 24 Mar 2018 08:09:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55 Sat 24 Mar 2018 07:42:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:24797 Mon 23 Sep 2019 14:21:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51403 Mon 04 Sep 2023 14:50:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46587 Misuse is not the main problem) contextualised misuse as a relatively minor concern compared with pain control and toxicity, and highlighted underlying systemic factors, including limitations in continuity of care and doctor expertise. Theme 2 (‘A different mindset’ for cancer pain) captured participants’ relative comfort in prescribing opioids for pain in cancer versus non-cancer contexts, and acknowledgement that compassion and greater perceived community acceptance were driving factors, in addition to scientific support for mechanisms and clinical efficacy. Participant attitudes towards prescribing for people with cancer versus non-cancer pain differed most when cancer was in the palliative phase, when they were unconcerned by misuse. Participants were equivocal about the risk–benefit ratio of long-term opioid therapy in the chronic phase of cancer, and were reluctant to prescribe for disease-free survivors. Theme 3 (‘The question is always, ‘how lazy have you been?’) captured participants’ acknowledgement that they sometimes prescribed opioids for cancer pain as a default, easier option compared with more holistic pain management. Conclusions: Findings highlight the role of specific clinical considerations in distinguishing risk of opioid misuse in the cancer versus non-cancer population, rather than diagnosis per se. Further efforts are needed to ensure continuity of care where opioid prescribing is shared. Greater evidence is needed to guide opioid prescribing in disease-free survivors and the chronic phase of cancer, especially in the context of new treatments for metastatic disease.]]> Fri 25 Nov 2022 14:52:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:34896 0.05). Our findings suggest that when making cancer treatment decisions, clinicians should consider offering patients and support persons written and online information, combined with two shorter consultations.]]> Fri 10 Mar 2023 17:39:19 AEDT ]]>